Global Rare Disease Contract Research Organization Market Size is Projected to Reach USD 5.06 Billion by 2035 | CAGR of 8.09%

Global Rare Disease Contract Research Organization Market Size is Projected to Reach USD 5.06 Billion by 2035 

According to a research report published by Spherical Insights & Consulting, the Global Rare Disease Contract Research Organization (CRO) Market is expected to grow from USD 2.15 billion in 2024 to USD 5.06 billion by 2035, at a CAGR of 8.09% during the forecast period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Rare Disease Contract Research Organization (CRO) Market Size, Share, and COVID-19 Impact Analysis, By Service Type (Drug Development Strategy, Clinical Trial Management, Data Management & Biostatistics, Regulatory & Consulting, and Other Specialist Services), By Therapeutic Area (Cardiovascular, Neuroscience, Ophthalmology, Oncology, and Metabolic & Other), By Phase (Pre-Clinical, Phase I, Phase II, Phase III, and Phase IV), By End-User (Pharma & Biotech Companies, Non-Profit & Gov’t Sponsors, Academic & Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Detailed Report Decription Here : https://www.sphericalinsights.com/reports/rare-disease-contract-research-organization-market

The rare disease contract research organization (CRO) market refers to the worldwide industry that involves specialized firms providing clinical trial operation, non-supervisory strategy, and drug development services for rare and orphan disease conditions. There is specialized and complex regulatory needs for drug development, especially for technical small biotech enterprises, which drives the need for CROs for precision drug, innovative trial designs, and patient case-centric. Traditional randomized controlled trials, AI & digital health, and cell & gene therapy are some of the key trends in the market in addition to major players’ growing R&D expenditure and expanding partnerships, which are driving industrial expansion. With the growing prevalence of rare diseases, regulations providing specialized framework for developing medicines are positively affecting the market demand. In addition, managing complex, small-cohort trials for rare diseases needs specialized CROs, which contributes to propelling market demand. However, an increased development cost, strict regulatory hurdles, lack of specialized site accessibility, and cross-border genomic-data privacy barriers are challenging the rare disease contract research organization (CRO) market.

The clinical trial management segment dominated the market with around 54.5% share in 2024 and is projected to grow at a substantial CAGR of nearly 9.15% during the forecast period.

Based on the service type, the rare disease contract research organization (CRO) market is divided into drug development strategy, clinical trial management, data management & biostatistics, regulatory & consulting, and other specialist services. Among these, the clinical trial management segment dominated the market with around 54.5% share in 2024 and is projected to grow at a substantial CAGR of nearly 9.15% during the forecast period. Decentralized trial logistics and real-time oversight demand are responsible for market growth in the clinical trial management segment.

The oncology segment accounted for the largest market share of around 35.0% in 2024 and is anticipated to grow at a remarkable CAGR of about 9.10% during the forecast period.

Based on the therapeutic area, the rare disease contract research organization (CRO) market is divided into cardiovascular, neuroscience, ophthalmology, oncology, metabolic & other. Among these, the oncology segment accounted for the largest market share of around 35.0% in 2024 and is anticipated to grow at a remarkable CAGR of about 9.10% during the forecast period. worldwide, there are more than 500 commercially available orphan-designated medications for a variety of uncommon illnesses, with oncology having the highest number. The oncology segment’s market growth is being driven by CAR-T and precision programs that target low-cancer prevalence.

The phase III segment accounted for the largest market share of around 56.0% in 2024 and is anticipated to grow at a remarkable CAGR of about 8.9% during the forecast period.

Based on the phase, the rare disease contract research organization (CRO) market is divided into pre-clinical, phase I, phase II, phase III, and phase IV. Among these, the phase III segment accounted for the largest market share of around 56.0% in 2024 and is anticipated to grow at a remarkable CAGR of about 8.9% during the forecast period. Phase III trials are intended to evaluate a new drug’s safety, efficacy, and effectiveness, which is usually an expensive and time-consuming procedure when carried out in a population with a rare condition.

The pharma & biotech companies segment held the largest share of around 71.5% in the rare disease contract research organization (CRO) market in 2024 and is expected to grow at a significant CAGR of around 8.7% during the forecast period.

Based on the end-user, the rare disease contract research organization (CRO) market is divided into pharma & biotech companies, non-profit & Gov’t sponsors, academic & research institutes, and others. Among these, the pharma & biotech companies segment held the largest share of around 71.5% in the rare disease contract research organization (CRO) market in 2024 and is expected to grow at a significant CAGR of around 8.7% during the forecast period. Companies with fewer than 50 employees outsource their major clinical operations to CROs, which contributes to driving the segmental market.

North America is expected to hold the majority share of the global rare disease contract research organization (CRO) market during the forecast period.

North America is expected to hold the majority share of around 46.7% in the global rare disease contract research organization (CRO) market during the forecast period. The United States is leading in the North America rare disease contract research organization (CRO) market, with about 84.9% regional share, owing to the robust biotechnology and pharmaceutical ecosystem and increasing clinical trials. North America has a robust market ecosystem due to CRO’s specialized services that navigate complex study designs. The region's increased volume of specialized therapeutic pipelines, significant regulatory incentives, and reliance on outsourcing complex small-cohort trials are driving the regional market for rare disease contract research organization (CRO).     

Asia Pacific is anticipated to grow at the fastest pace of around 9.4% in the global rare disease contract research organization (CRO) market during the forecast period. China is the dominating country in the Asia Pacific rare disease contract research organization (CRO) market, with over 80.0% share, driven by massive patient population and huge R&D investment. In the Asia Pacific rare disease contract research organization (CRO) market, there is an increasing demand for efficient drug development and the region’s extensive patient population for conducting clinical trials. Further, collaborative initiatives among healthcare professionals, researchers, patient organizations, and government entities are contributing to propel the rare disease contract research organization market.  

Major vendors in the global rare disease contract research organization (CRO) market are Allucent, Caidya, Charles River Labs, Ergomed, Fortrea, ICON plc, IQVIA, Labcorp Drug Development, Linical, Medpace, Novotech, Orphan-Reach, Parexel, Syneos Health, and Others.   

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In February 2026, Polaryx Therapeutics, Inc. announced it has selected a contract research organization (CRO) to conduct SOTERIA, a phase 2 trial evaluating its lead candidate PLX-200 across four rare lysosomal storage disorders (LSDs).

• In January 2026, Mendra, Inc., a biopharmaceutical company built to advance promising therapies for rare disease medicines, utilizing artificial intelligence (AI), announced its launch in conjunction with the closing of an $82 million oversubscribed Series A financing.

• In October 2025, IDDI Strengthens Position as Contract Research Organization with Advanced Clinical Trial Design Solutions. The company’s advanced statistical methodologies and adaptive trial design capabilities are addressing critical challenges in drug development while improving efficiency, accuracy, and success rates of clinical trials.

• In April 2025, Comac Medical, a leading full-service Contract Research Organization (CRO) in Central and Eastern Europe, announced the appointment of a new CEO and Board Chair and the launch of an international expansion initiative.  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the rare disease contract Research organization (CRO) market based on the below-mentioned segments:

Global Rare Disease Contract Research Organization (CRO) Market, By Service Type

• Drug Development Strategy
• Clinical Trial Management
• Data Management & Biostatistics
• Regulatory & Consulting
• Other Specialist Services

Global Rare Disease Contract Research Organization (CRO) Market, By Therapeutic Area

• Cardiovascular
• Neuroscience
• Ophthalmology
• Oncology
• Metabolic & Other

Global Rare Disease Contract Research Organization (CRO) Market, By Phase

• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Global Rare Disease Contract Research Organization (CRO) Market, By End-User

• Pharma & Biotech Companies
• Non-Profit & Gov’t Sponsors
• Academic & Research Institutes
• Others

 Global Rare Disease Contract Research Organization (CRO) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 
CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter